IRLAB Therapeutics AB
STO:IRLAB A
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Zynex Inc
NASDAQ:ZYXI
|
Health Care
|
| US |
|
PepsiCo Inc
NASDAQ:PEP
|
Beverages
|
| IL |
|
Inmode Ltd
NASDAQ:INMD
|
Health Care
|
| UK |
|
Macfarlane Group PLC
LSE:MACF
|
Trading Companies & Distributors
|
| UK |
|
4imprint Group PLC
LSE:FOUR
|
Media
|
| UK |
|
Moneysupermarket.Com Group PLC
LSE:MONY
|
Media
|
| UK |
|
IG Group Holdings PLC
LSE:IGG
|
Financial Services
|
| UK |
|
Gaming Realms PLC
LSE:GMR
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.9
19.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Zynex Inc
NASDAQ:ZYXI
|
US |
|
|
PepsiCo Inc
NASDAQ:PEP
|
US |
|
|
Inmode Ltd
NASDAQ:INMD
|
IL |
|
|
Macfarlane Group PLC
LSE:MACF
|
UK |
|
|
4imprint Group PLC
LSE:FOUR
|
UK |
|
|
Moneysupermarket.Com Group PLC
LSE:MONY
|
UK |
|
|
IG Group Holdings PLC
LSE:IGG
|
UK |
|
|
Gaming Realms PLC
LSE:GMR
|
UK |
This alert will be permanently deleted.
IRLAB Therapeutics AB
IRLAB Therapeutics AB
Accounts Payable
IRLAB Therapeutics AB
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
IRLAB Therapeutics AB
STO:IRLAB A
|
Accounts Payable
kr10.5m
|
CAGR 3-Years
42%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Calliditas Therapeutics AB
STO:CALTX
|
Accounts Payable
kr151m
|
CAGR 3-Years
37%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Camurus AB
STO:CAMX
|
Accounts Payable
kr78.4m
|
CAGR 3-Years
35%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Accounts Payable
kr116.7m
|
CAGR 3-Years
65%
|
CAGR 5-Years
93%
|
CAGR 10-Years
N/A
|
|
|
Moberg Pharma AB (publ)
STO:MOB
|
Accounts Payable
kr6.8m
|
CAGR 3-Years
32%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Accounts Payable
kr6.7m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
IRLAB Therapeutics AB
Glance View
IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
See Also
What is IRLAB Therapeutics AB's Accounts Payable?
Accounts Payable
10.5m
SEK
Based on the financial report for Dec 31, 2023, IRLAB Therapeutics AB's Accounts Payable amounts to 10.5m SEK.
What is IRLAB Therapeutics AB's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
12%
Over the last year, the Accounts Payable growth was 5%. The average annual Accounts Payable growth rates for IRLAB Therapeutics AB have been 42% over the past three years , 12% over the past five years .
You don't have any saved screeners yet
